Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A compound of formula (IE) or a salt, N-oxide, hydrate or solvate thereof, for use in human or veterinary medicine:



(IE)

wherein R_1 has the formula (IIA):



(IIA)

wherein R represents bromo, chloro, phenyl, C_1-C_6 alkyl or phenyl(C_1-C_6 alkyl)

~~R_1 is a group of formula (II):~~



~~wherein in any compatible combination~~

~~Alk^1 and Alk^2 are optionally substituted divalent C_1-C_6 alkylene or C_2-C_6 alkenylene radicals,~~

~~p, r and s are independently 0 or 1,~~

~~Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO_2-, -C(=O)O-, -C(=O)NR^A-, -C(=S)NR^A-, -SO_2NR^A-, -$NR^AC(=O)$-, -NR^ASO_2- or -NR^A- wherein R^A is hydrogen or C_1-C_6 alkyl,~~

~~Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical, and R represents hydrogen or one or more substituents selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy, hydroxy(C_1-C_6)alkyl, mercapto, mercapto(C_1-C_6)alkyl, (C_1-C_6)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, -$COOR^A$, -COR^A, -SO_2R^A, -$CONH_2$, -SO_2NH_2, -$CONHR^A$, -SO_2NHR^A, -$CONR^AR^B$, -$SO_2NR^AR^B$, -NH_2, -NHR^A, -NR^AR^B, -$OCONH_2$, -$OCONHR^A$, -$OCONR^AR^B$, -$NHCOR^A$, -$NHCOOR^A$, -NR^BCOOR^A, -$NHSO_2OR^A$, -$NR^BSO_2OR^A$, -$NHCONH_2$, -NR^ACONH_2, -$NHCONHR^B$, -NR^ACONHR^B, -$NHCONR^AR^B$, or -$NR^ACONR^AR^B$ wherein R^A and R^B are independently a (C_1-C_6)alkyl group.~~

R_2 is hydrogen or

~~(i) a group of formula (IA) as defined in relation to R_1;.~~

~~(ii)~~ a carboxamide radical; or

~~(iii)~~ a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -$(Alk^1)_p$-$(Z)_r$$(Alk^2)_s$-Q wherein ~~Q, Alk^1, Alk^2, Z, p, r and s are as defined above in relation to group (IA);~~ in any compatible combination

Alk^1 and Alk^2 are divalent C_1-C_6 alkylene or C_2-C_6 alkenylene radicals,

p, r and s are independently 0 or 1,

Z is -O-, -S-, -(C=O)-, -(C=S)-, -SO_2-, -C(=O)O-, -C(=O)NR^A-, -C(=S)NR^A-, -SO_2NR^A-, -$NR^AC(=O)$-, -NR^ASO_2- or -NR^A- wherein R^A is hydrogen or C_1-C_6 alkyl, and

Q is hydrogen or a carbocyclic or heterocyclic radical;

wherein each of Alk^1, Alk^2, and Q are optionally substituted with one or more substituents selected from (C_1-C_6)alkyl, (C_1-C_6)alkoxy, hydroxy, hydroxy(C_1-C_6)alkyl, mercapto, mercapto(C_1-C_6)alkyl, (C_1-C_6)alkylthio, halo (including fluoro and chloro), trifluoromethyl, trifluoromethoxy, nitro, nitrile (-CN), oxo, phenyl, -COOH, $-COOR^A$, $-COR^A$, $-SO_2R^A$, $-CONH_2$, $-SO_2NH_2$, $-CONHR^A$, $-SO_2NHR^A$, $-CONR^AR^B$, $-SO_2NR^AR^B$, $-NH_2$, $-NHR^A$, $-NR^AR^B$, $-OCONH_2$,--OCONHR^A, $-OCONR^AR^B$, $-NHCOR^A$, $-NHCOOR^A$, $-NR^BCOOR^A$, $-NHSO_2OR^A$, $-NR^BSO_2OR^A$, $-NHCONH_2$, $-NR^ACONH_2$, $-NHCONHR^B$, $-NR^ACONHR^B$, $-NHCONR^AR^B$, or --$NR^ACONR^AR^B$, wherein R^A and R^B are independently a (C_1-C_6)alkyl group; and

R_3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C_1-C_6 alkyl, C_2-C_6 alkenyl, or C_2-C_6alkynyl; or a carboxyl, carboxamide or carboxyl ester group,

PROVIDED THAT at least one of R_2 and R_3 is present and is other than hydrogen.

Claims 2-14 (Canceled)

15. (Previously Presented) The compound as claimed in claim 1 wherein R_2 is phenyl, 2-, 3-, or 4-pyridyl, 2- or 3-furanyl, 2- or 3-thienyl, or thiazolyl, optionally substituted by one or more of methoxy, ethoxy, methylenedioxy, ethylenedioxy, fluoro, chloro, bromo, or trifluoromethyl.

16. (Previously Presented) The compound as claimed in claim 1 wherein R_2 is optionally substituted phenyl.

17. (Withdrawn) The compound as claimed in claim 1 wherein R_2 is a carboxamide radical of formula $-CONR^B(Alk)_nR^A$ wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R^B is hydrogen or a C_1-C_6 alkyl or C_2-C_6 alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

18. (Withdrawn – Currently Amended) The compound as claimed in claim 17 wherein

Alk is an optionally substituted $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $CH_2CH=CH-$, or $-CH_2CCCH_2-$ radical.

n is 0 or 1 ,

R^B is hydrogen, methyl, ethyl, n- or iso-propyl, or allyl,

R^A is hydroxy, hydroxy and/or chloro-substituted phenyl, 3,4 methylenedioxyphenyl, pyridyl, furyl, thienyl, N-piperazinyl, or Nmorpholinyl,

or R^A and R^B taken together with the nitrogen to which they are attached form a morpholino, piperidinyl, piperazinyl or N-phenylpiperazinyl ring.

19. (Withdrawn) The compound as claimed in claim 17 wherein n is 0, R^B is hydrogen and R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring.

20. (Withdrawn) The compound as claimed in claim 1 wherein R_3 is hydrogen, methyl, ethyl, n- or iso-propyl, trifluoromethyl, or hydroxyethyl.

21. (Withdrawn) The compound as claimed in claim 1 wherein R_3 is a carboxamide group $-CONR^B(Alk)_nR^A$ wherein

Alk is an optionally substituted divalent alkylene, alkenylene or alkynylene radical,

n is 0 or 1,

R^B is hydrogen or a C_1-C_6 alkyl or C_2-C_6 alkenyl group,

R^A is hydroxy or an optionally substituted carbocyclic or heterocyclic ring,

or R^A and R^B taken together with the nitrogen to which they are attached form an N-heterocyclic ring which may optionally contain one or more additional hetero atoms selected from O, S and N, and which may optionally be substituted on one or more ring C or N atoms.

22. (Withdrawn) A method of treatment of diseases or conditions mediated by excessive or inappropriate HSP90 activity in mammals which method comprises administering to the mammal an amount of a compound of formula (IE) as defined in claim 1 , or a salt, hydrate or solvate thereof, effective to inhibit said HSP90 activity.

23. (Withdrawn) The method as claimed claim 22 for immunosuppression or the treatment of cancer; viral disease, inflammatory diseases such as rheumatoid arthritis, asthma, multiple sclerosis, Type I diabetes, lupus, psoriasis and inflammatory bowel disease; cystic fibrosis angiogenesis-related disease such as diabetic retinopathy, haemangiomas, and endometriosis; or for protection of normal cells against chemotherapy-induced toxicity; or diseases where failure to undergo apoptosis is an underlying factor; or protection from hypoxia-ischemic injury due to elevation of Hsp70 in the heart and brain; scrapie/CJD, Huntingdon's and Alzheimer's disease.

24. (Canceled)

25. (Previously Presented) A pharmaceutical or veterinary composition comprising a compound as defined in claim 1, or a salt hydrate or solvate thereof, together with a pharmaceutically or veterinarily acceptable carrier.